

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Simcere Pharmaceutical Group Limited

先聲藥業集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 2096)

**VOLUNTARY ANNOUNCEMENT
ENTERING INTO AN EXCLUSIVE LICENSE AND
COLLABORATION AGREEMENT WITH CONNECT BIOPHARMA IN
RELATION TO IL-4R α MONOCLONAL ANTIBODY RADEMIKIBART**

This announcement is made by Simcere Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders and potential investors of the Company about the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that, on November 21, 2023, the Group entered into an exclusive license and collaboration agreement (the “**Agreement**”) with Connect Biopharma HongKong Limited (香港康乃德生物醫藥有限公司) (“**Connect Biopharma**”) in relation to Rademikibart (the “**Product**”), an innovative IL-4R α monoclonal antibody. Pursuant to the Agreement, the Group will obtain the exclusive rights in relation to the development, manufacturing and commercialization of all indications of the Product in Greater China (the “**Territory**”). Connect Biopharma will retain its rights in respect of the Product outside the Territory and will continue to be responsible for and complete the ongoing clinical trials of the Product. The Group will be independently responsible for conducting future clinical trials and developing new indications of the Product in the Territory.

According to the terms of the Agreement, Connect Biopharma will receive an upfront payment of RMB150 million (approximately US\$21 million), up to RMB875 million (approximately US\$125 million) upon achieving certain development and commercial milestones, and additional royalties up to low double-digit percentages of net sales.

ABOUT RADEMIKIBART

Rademikibart (CBP-201) is a fully human monoclonal antibody targeting IL-4R α , a common subunit of IL-4 receptor and IL-13 receptor. By binding with IL-4R α , Rademikibart can block the functions of IL-4 and IL-13 effectively, thereby blocking the Th2 inflammatory pathway, thus achieving the goal of treating Th2 related inflammatory diseases such as atopic dermatitis and asthma. Currently, Rademikibart is being simultaneously tested in the pivotal clinical trial and other related clinical trials for atopic dermatitis in China, and a phase II clinical trial for asthma globally.

ABOUT CONNECT BIOPHARMA

Connect Biopharma is a biopharmaceutical company with clinical-stage products and a global presence. By applying expertise in T cell biology and deep knowledge of the drug discovery industry, Connect Biopharma develops innovative therapies to treat chronic inflammatory diseases with the goal of improving the lives of millions of those affected around the world. Connect Biopharma is building a rich pipeline of proprietary small molecules and antibodies, using functional T cell assays, to screen and discover potent product candidates against validated immune targets.

ABOUT THE COMPANY

The Company is an innovation and R&D-driven pharmaceutical company and has established a “State Key Laboratory of Neurology and Oncology Drug Development”. The Company focuses on the therapeutic areas of oncology, nervous system, autoimmune and anti-infection, with forward-looking layout of disease areas that may have significant clinical needs in the future, aiming to achieve the mission of “providing today’s patients with medicines of the future”. Driven by its in-house R&D efforts and synergistic innovation, the Company has established strategic cooperation partnerships with many innovative companies and research institutes.

LISTING RULES IMPLICATIONS

The entering into the Agreement does not constitute a disclosable transaction under Chapter 14 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) as none of the applicable percentage ratios (as defined in Rule 14.07 of the Listing Rules) in respect of the transactions contemplated under the Agreement exceeds 5%.

To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, Connect Biopharma and its ultimate beneficial owners are all third parties independent of the Company and its connected persons (as defined under the Listing Rules).

By order of the Board
Sincere Pharmaceutical Group Limited
Mr. Ren Jinsheng
Chairman and Chief Executive Officer

Hong Kong, November 21, 2023

As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director, Mr. TANG Renhong, Mr. WAN Yushan and Ms. WANG Xi as the executive Directors; and Mr. SONG Ruilin, Mr. WANG Jianguo, Mr. WANG Xinhua and Mr. SUNG Ka Woon as the independent non-executive Directors.